Overview

Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients

Status:
Completed

Trial end date:
2017-01-24

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare tacrolimus dosing of the new Envarsus®-based immunosuppressive regimen with current clinical practice (Prograf or Advagraf) over 6 months following de novo renal transplantation in a real-life setting in different European Countries.

Phase:

Phase 4

Details

Lead Sponsor:

Chiesi Farmaceutici S.p.A.

Treatments:

Tacrolimus